Cerebrolysin

What Cerebrolysin is

Cerebrolysin is an injectable preparation made through enzymatic breakdown of purified porcine brain proteins. It contains low-molecular-weight peptides and amino acids in an aqueous solution. The manufacturer lists 215.2 mg of Cerebrolysin concentrate per milliliter, making each 5 mL administration in this experiment approximately 1,076 mg.

Why it was worth testing

The interesting claim was not ordinary stimulation. Cerebrolysin is positioned around neurotrophic and neurorecovery mechanisms, creating a plausible personal question about cleaner cognitive energy, faster mental activation after waking, steadier focus, and lower emotional friction. The experiment tested those observable outcomes rather than treating the proposed mechanism as the result.

What the clinical evidence can answer

Human trials have mainly studied people with diagnosed neurological conditions. A randomized Alzheimer's disease trial, for example, studied intravenous 10, 30, and 60 mL courses in 279 patients and reported cognitive and global-outcome signals at some doses. That is useful evidence that Cerebrolysin has been studied as an active neurological intervention, but it does not establish cognitive enhancement in a healthy adult or validate this 5 mL daily IM course.

Route and administration context

Manufacturer guidance lists undiluted intramuscular administration up to 5 mL and describes slow administration. The experiment stayed at that per-administration volume. This page records what I used and what happened; it is not an administration guide.

Interaction decision

I stopped 5-HTP before the course because the manufacturer warns that Cerebrolysin may have additive effects with antidepressants and MAO inhibitors. 5-HTP is neither an antidepressant drug nor an MAO inhibitor, but it is a serotonin precursor and there were no useful combination data. Removing it reduced an avoidable uncertainty.

None of the other logged stack items was being used as an antidepressant or MAO inhibitor. Bromantane remained a familiar daily background exposure, and Modafiendz was not used on the reported days.

Sources

• Manufacturer prescribing information — composition, indications, contraindications, and regulatory context.
• Manufacturer administration guidance — route, volume, and handling information.
• Cerebrolysin treatment handbook — clinical context, interactions, and practical safety information.
• Alzheimer's disease randomized controlled trial — cognitive evidence in a diagnosed disease population.
• Clinical safety review — adverse-event experience across dementia and stroke trials.
• 5-HTP review — serotonin-precursor context for the conservative stack change.

The question

Would a short Cerebrolysin course produce a clear, repeatable change in morning mental clarity, energy, sustained focus, productivity, mood, rumination, or stress tolerance without creating an unacceptable sleep, cardiovascular, neurological, or injection-site cost?

Protocol as run

I used 5 mL intramuscularly once daily for ten consecutive days, August 15–24, 2026. The complete course was 50 mL, or approximately 10,760 mg at the manufacturer's stated 215.2 mg/mL concentration. The first administration occurred on a Zone 2 cardio day. Follow-up continued through September 1.

This was a deliberate change from the original five-dose, every-other-day 10 mL plan. I switched before the first dose to 5 mL daily for ten days. Administration time varied from 7:00 AM to 6:00 PM as the experiment progressed, so this ultimately tested the daily course rather than a fixed time-of-day protocol.

Reference and monitoring structure

There was no separate pre-course baseline. The Day 1 wake-up reading, collected before the first administration, became the reference: mental clarity 4/10, energy 3/10, and mood 3/10 after four hours of sleep. That makes within-course repetition and post-course persistence more important than a single before-and-after comparison.

Monitoring used four practical windows: wake-up, approximately one to three hours after the shot, midday, and end of day. Subjective measures included clarity, focus, energy, fatigue, mood, stress tolerance, rumination, productivity, task friction, activation, headache, and other symptoms. Home measurements included sleep, resting heart rate, HRV, blood pressure, body weight, urine appearance, and injection-site pain, stiffness, and visible changes.

Final result

I am closing the experiment as helpful. The predefined cognitive threshold was met, the improvement repeated across the course, usable productivity ratings agreed with it, and the signal remained present after the final administration. No systemic adverse pattern or unresolved injection-site problem offset the result.

Mental clarity and energy

Day 1 started at clarity 4/10 and energy 3/10. Across the eight later administration mornings with complete subjective data, clarity was at least two points above Day 1 on six mornings, and energy was at least two points above Day 1 on six mornings. The final administration morning reached clarity 8/10 and energy 7/10.

The first dose did not produce an immediate one-hour change: clarity was still 4/10 at 1:00 PM. The change emerged later that day, reaching clarity 6/10 at 3:30 PM and 7/10 by end of day. Mood moved from 3/10 before the first dose to 6/10 midday and 7/10 at the final check. That delayed first-day pattern was more useful than a simple injection rush and then repeated on later days.

Focus, productivity, and task friction

Usable daytime and end-of-day ratings generally placed focus, productivity, and mental performance around 7–8/10, while cognitive fatigue was commonly 0–3/10. Task friction was usually low when it was collected. No formal psychomotor-vigilance test was completed, so productivity served as the functional corroboration rather than an objective reaction-time endpoint.

Mood and emotional control

Mood improved with the early cognitive signal, but the more distinctive result appeared late in follow-up. By August 31 I had noticed three to four days of easier recovery from emotional spikes, less anger, less annoyance, and a shorter duration when those feelings did occur. I rated the effect 7/10 in importance and described it as consistent. The supplementary September 1 check rated emotional control 9/10 and confirmed that the effect was still present.

Administration record

Morning trajectory during administration

Em dashes indicate a missed subjective round, not a zero score.

Post-course follow-up

Decision-rule scorecard

• Magnitude: met. Clarity and energy repeatedly cleared the planned two-point improvement threshold.
• Repetition: met. The signal appeared across multiple administration days rather than after one isolated dose.
• Persistence: met. Clarity remained 7–8/10 and energy 6–8/10 across the collected follow-up observations.
• Functional agreement: met subjectively. Productivity was generally 7–8/10, although no formal reaction-time test was completed.
• Tolerability: met. Injection discomfort was real but temporary, and no unacceptable systemic or sleep penalty emerged.

Injection-site tolerability

The main cost was the 5 mL injection volume. Immediate pain ranged from 3/10 to 7/10, typically described as deep pressure, muscle pain, or stiffness rather than sharp, shooting, or radiating pain. Brief muscle spasms occurred on several days. Minor bleeding occurred twice and stopped promptly.

There was no persistent redness, warmth, swelling, drainage, numbness, weakness, or difficulty walking. Earlier sites progressively became pain-free, and all injection sites were confirmed symptom-free by the Day 13 follow-up.

Systemic symptoms, blood pressure, and wearables

There was no consistent headache, nausea, dizziness, wired feeling, unusual activation, agitation, or neurological symptom during the course. Resting heart rate and HRV varied without a convincing trend. Blood pressure was generally in my low-normal range. The lowest reading was 93/52 on Day 8, improving to 98/50 five minutes later; it was not accompanied by symptoms and did not become a persistent pattern.

Sleep

Sleep was short and variable throughout the experiment. Recorded administration-period mornings averaged approximately 4.4 hours of sleep with about 87% efficiency. Collected follow-up mornings averaged approximately 5.5 hours with about 91% efficiency. The clearest bad night followed a misplaced evening Cyclean AM exposure and included sweating and nausea; those effects resolved. I did not observe a repeatable pattern linking Cerebrolysin itself to worse sleep.

What did not produce a clear signal

HRV, resting heart rate, blood pressure, and sleep did not show a consistent improvement. The experiment also did not produce a formal PVT or another objective cognitive score. The strongest result is therefore the repeated subjective cognitive pattern, functional productivity agreement, and post-course emotional-control observation—not a wearable or laboratory endpoint.

Interpretation and confounders

The cognitive timing is the cleanest part of the result. Clarity, energy, mood, and productivity improved during Days 1–3, before BAM-15 entered the record, and the pattern repeated afterward. Bromantane remained at the familiar 50 mg daily background dose, Modafiendz was not used on reported days, and caffeine was treated as a stable everyday exposure.

SANA was not perfectly stable across the early course: the logged amount increased before settling into the later 200 mg after waking and 200 mg before sleep pattern. BAM-15 began on Day 10 and escalated during follow-up. That means the late emotional-regulation result was observed during the combined Cerebrolysin follow-up and BAM-15 period. I still count it as a meaningful personal outcome, but attribution for that specific late effect is shared. The earlier cognitive change is less exposed to that confounder.

Several post-shot and midday windows were missed, especially when I was away from home. Morning and end-of-day measurements are therefore the strongest longitudinal comparisons. The absence of a separate baseline and formal objective testing limits precision, but the repeated size and persistence of the subjective change were enough to satisfy the rule defined for this experiment.

What I would change in a future repeat

• Collect seven days of identical pre-course baseline ratings.
• Keep all other compound amounts unchanged through administration and follow-up.
• Use a fixed administration time and fixed check-in offsets.
• Add one short daily objective cognitive task, ideally PVT or a consistent reaction-time test.
• Take two seated blood-pressure readings at each planned cardiovascular check.
• Predefine the exact follow-up days and complete them even when the administration phase has ended.

Final decision

The experiment is closed as a meaningful positive result. Cerebrolysin cleared the cognitive threshold, the effect survived the end of the dosing window, and the later emotional-control observation was personally valuable. No additional experiment monitoring is pending; this page is the final record for the August 2026 course.